Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors
characterized by acquired heterogenous genetic changes that alter normal mechanisms of …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC)
patients with EGFR mutations and their sensitivity to classical epidermal growth factor …

Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small
cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 …

Acute myeloid leukaemia ( AML ) with FLT3 mutation has a dismal prognosis in elderly
patients. Treatment with a combination of FLT 3 inhibitors and standard chemotherapy has not …

It is well-known that sex hormones can directly and indirectly influence immune cell function.
Different studies support a suppressive role of androgens on different components of the …

Tumors of the head and neck represent a molecularly diverse set of human cancers, but
relatively few proteins have actually been shown to drive the disease at the molecular level. To …

Up to 40% of advance lung, melanoma and breast cancer patients suffer from brain metastases
(BM) with increasing incidence. Here, we assessed whether circulating tumor cells (CTCs…

Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with
the emergence of oncogene targeted therapies, treatment options have tremendously …

Background EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell
lung cancer (NSCLC). However, data about outcome under conventional therapies …

Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of
response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we …